# NCT03671018 (NCT03671018)

> A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma

No report yet. It can be ordered.

- Drugs tested: mosunetuzumab plus polatuzumab vedotin
- Indication: relapsed or refractory B-cell non-Hodgkin lymphoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03671018
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Hoffmann-La Roche
- Conditions: B-cell Non-Hodgkin Lymphoma
- Interventions: Mosunetuzumab (IV); Mosunetuzumab (SC); Polatuzumab vedotin; Tocilizumab; Rituximab
- Enrollment: 422
- Primary outcome: Maximum Tolerated Dose (MTD) of Mosunetuzumab in Combination with Polatuzumab Vedotin
- Primary outcome: Recommended Phase II Dose of Mosunetuzumab in Combination with Polatuzumab Vedotin
- Primary outcome: Percentage of Participants with Adverse Events (AE)
- Primary outcome: Best Objective Response Rate (ORR), Defined as CR or Partial Response (PR) at any Time, Based on PET-CT and/or CT Scan, as Determined by the Independent Review Committee (IRC) using Standard Criteria for NHL

## Indexed commentary on NCT03671018 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 5

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct03671018